On August 5, 2021, Heymach, John; Robichaux, Jacqulyne published a patent.Safety of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine The title of the patent was Use of quinazoline-based tyrosine kinase inhibitors for the treatment of cancers with NRG1 fusions. And the patent contained the following:
Provided herein are methods of selecting cancer patients for treatment with quinazoline-based tyrosine kinase inhibitors, either alone or in combination with anti-HER2/HER3 antibodies, as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with quinazoline-based tyrosine kinase inhibitors alone or in combination with anti-HER2/HER3 antibodies. The experimental process involved the reaction of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine(cas: 175357-98-9).Safety of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine
The Article related to tyrosine kinase inhibitor quinazoline her antibody nrg1 fusion cancer, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Safety of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia